Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : MVA-based SARS-CoV-2 Vaccine
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Advanced Bioscience laboratories
Deal Size : Undisclosed
Deal Type : Agreement
GeoVax Partners With ABL to Advance cGMP Production of Vaccine Candidates
Details : The partnership will support current Good Manufacturing Practices production of the company’s vaccine candidates, including GEO-MVA and GEO-CM04S1 (MVA-based SARS-CoV-2 vaccine), a next-generation COVID-19 vaccine based on GeoVax’s MVA viral vector p...
Brand Name : GEO-CM04S1
Molecule Type : Vaccine
Upfront Cash : Undisclosed
May 31, 2023
Lead Product(s) : MVA-based SARS-CoV-2 Vaccine
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Advanced Bioscience laboratories
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : GEO-CM04S1
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : EmVenio Research
Deal Size : Undisclosed
Deal Type : Collaboration
GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial
Details : GEO-CM04S1 is a synthetic attenuated modified vaccinia Ankara (sMVA) vector vaccine that expresses spike and nucleocapsid antigens of the SARS-CoV-2 (COVID-19) virus.
Brand Name : GEO-CM04S1
Molecule Type : Vaccine
Upfront Cash : Undisclosed
February 15, 2023
Lead Product(s) : GEO-CM04S1
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : EmVenio Research
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Ad/PNP,Fludarabine Phosphate
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers
Details : Gedeptin (Ad/PNP) is a gene-directed enzyme prodrug therapy (GDEPT) that results in the formation of the oncolytic agent within the tumor itself, resulting in tumor cell death while significantly limiting systemic exposure.
Brand Name : Gedeptin
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
February 07, 2023
Lead Product(s) : Ad/PNP,Fludarabine Phosphate
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : COH04S1
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : City of Hope
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : A COVID-19 investigational vaccine COH04S1, elicited neutralizing antibodies against the virus’ spike protein also, produced a robust neutralizing antibody and T cell response against SARS-CoV-2 with no significant side effects in Phase 1 clinical tria...
Brand Name : COH04S1
Molecule Type : Vaccine
Upfront Cash : Not Applicable
March 10, 2022
Lead Product(s) : COH04S1
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : City of Hope
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : GEO-CM02
Therapeutic Area : Infections and Infectious Diseases
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
GeoVax Presents COVID-19 Vaccine Data at the Vaccine World Asia Congress
Details : GeoVax’s vaccine design strategy for developing a universal SARS-CoV-2 vaccine and presented efficacy and immunogenicity data for the Company’s lead vaccine candidate, GEO-CM02, which encodes the Spike (S), Membrane (M) and Envelope (E) proteins.
Brand Name : GEO-CM02
Molecule Type : Vaccine
Upfront Cash : Not Applicable
November 17, 2021
Lead Product(s) : GEO-CM02
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : GEO-CM01
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Recipient : National Institutes of Health
Deal Size : Undisclosed
Deal Type : Licensing Agreement
GeoVax Announces License Agreement with NIH to Support COVID-19 Vaccine Development
Details : The Patent License Agreement to GeoVax includes access to NIAID’s patent rights in the stabilized SPIKE protein, which is the protein that SARS-CoV-2 uses to gain entry into human tissue.
Brand Name : GEO-CM01
Molecule Type : Vaccine
Upfront Cash : Undisclosed
October 26, 2020
Lead Product(s) : GEO-CM01
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Recipient : National Institutes of Health
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : MVA-MARV-VLP vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The study demonstrated that guinea pigs vaccinated with GeoVax’s developmental MVA-MARV-VLP vaccine were 100% protected against death and disease caused by the Angola strain of Marburg virus.
Brand Name : Undisclosed
Molecule Type : Vaccine
Upfront Cash : Not Applicable
September 03, 2020
Lead Product(s) : MVA-MARV-VLP vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : COVID-19 vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Discovery
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
GeoVax Provides Update on Coronavirus (COVID-19) Vaccine Development Program
Details : GeoVax is using its GV-MVA-VLPTMvaccine platform and expertise to design and construct vaccine candidates using genetic sequences from the virus responsible for the ongoing COVID-19.
Brand Name : Undisclosed
Molecule Type : Vaccine
Upfront Cash : Not Applicable
March 04, 2020
Lead Product(s) : COVID-19 vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : GOVX-B11
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
GeoVax Prepared to Advance GOVX-B11 HIV Vaccine
Details : An independent data and safety monitoring board (DSMB) found during an interim review that the regimen did not prevent HIV infection.
Brand Name : Undisclosed
Molecule Type : Vaccine
Upfront Cash : Not Applicable
February 06, 2020
Lead Product(s) : GOVX-B11
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?